MX2012003591A - Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso. - Google Patents

Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso.

Info

Publication number
MX2012003591A
MX2012003591A MX2012003591A MX2012003591A MX2012003591A MX 2012003591 A MX2012003591 A MX 2012003591A MX 2012003591 A MX2012003591 A MX 2012003591A MX 2012003591 A MX2012003591 A MX 2012003591A MX 2012003591 A MX2012003591 A MX 2012003591A
Authority
MX
Mexico
Prior art keywords
methods
inhibitor compounds
pi3k inhibitor
benzoxazepin
compounds
Prior art date
Application number
MX2012003591A
Other languages
English (en)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Adrian J Folkes
Robert Heald
Timothy Heffron
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Mark Jones
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012003591(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012003591A publication Critical patent/MX2012003591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención se refiere a compuestos de benzoxazepina de la fórmula I (ver fórmula (I)) incluidos los estereoisómeros, isómeros geométricos, tautómeros y las sales farmacéuticamente aceptables de los mismos, en la que: Z1 es CR1 o N; Z2 es CR2 o N; Z3 es CR3 o N; Z4 es CR4 o N; y B es un anillo pirazolilo, imidazolilo o triazolilo fusionado con el anillo de la benzoxazepina, dichos compuestos tienen actividad anticancerosa y, más específicamente, inhiben la actividad de la quinasa PI3.
MX2012003591A 2009-09-28 2010-09-27 Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso. MX2012003591A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (en) 2009-09-28 2010-09-27 Benzoxazepin pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2012003591A true MX2012003591A (es) 2012-04-19

Family

ID=43037239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003591A MX2012003591A (es) 2009-09-28 2010-09-27 Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso.

Country Status (32)

Country Link
US (7) US8242104B2 (es)
EP (3) EP2483278B1 (es)
JP (2) JP5540101B2 (es)
KR (1) KR101428346B1 (es)
CN (2) CN104744491B (es)
AR (1) AR078187A1 (es)
AU (1) AU2010299816C1 (es)
BR (1) BR112012006807A2 (es)
CA (1) CA2772691C (es)
CL (1) CL2012000754A1 (es)
CO (1) CO6491026A2 (es)
CR (1) CR20120121A (es)
DK (1) DK2483278T3 (es)
EC (1) ECSP12011755A (es)
ES (2) ES2570569T3 (es)
HK (2) HK1174629A1 (es)
HR (1) HRP20140229T1 (es)
IL (2) IL217558A (es)
MA (1) MA33531B1 (es)
MX (1) MX2012003591A (es)
MY (2) MY160064A (es)
NZ (1) NZ597833A (es)
PE (1) PE20121025A1 (es)
PL (1) PL2483278T3 (es)
PT (1) PT2483278E (es)
RS (1) RS53164B (es)
RU (2) RU2600927C2 (es)
SG (1) SG10201405049RA (es)
SI (1) SI2483278T1 (es)
TW (1) TWI423980B (es)
WO (1) WO2011036280A1 (es)
ZA (1) ZA201202199B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
SG10201405049RA (en) * 2009-09-28 2014-10-30 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
BR112012006802A2 (pt) 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
KR20140032383A (ko) 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) * 2011-07-01 2018-04-28
KR20140131359A (ko) * 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 트라이사이클릭 화합물 및 이의 사용 방법
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
EP2882757B1 (en) * 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
MX2015011438A (es) * 2013-03-13 2016-02-03 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina.
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105829323B (zh) * 2013-12-16 2019-04-12 豪夫迈·罗氏有限公司 Gdc-0032的多晶型物、其制备方法和药物用途
CN106572990A (zh) 2014-03-13 2017-04-19 豪夫迈·罗氏有限公司 含有***受体调节剂的治疗性组合产品
CA2990165C (en) 2015-02-02 2023-12-12 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
US10351576B2 (en) * 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
MX2017016346A (es) 2015-06-29 2018-05-02 Hoffmann La Roche Metodos de tratamiento con taselisib.
PL3567045T3 (pl) * 2015-07-02 2022-04-19 F. Hoffmann-La Roche Ag Związki benzoksazepinooksazolidynonowe i sposoby zastosowania
JP6522807B2 (ja) * 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
JP6873977B2 (ja) 2015-09-08 2021-05-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三環式ｐｉ３ｋ阻害化合物及び使用方法
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2017333782A1 (en) 2016-09-29 2019-03-28 Bayer Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
ES2953833T3 (es) * 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
RS65204B1 (sr) 2017-03-02 2024-03-29 Genentech Inc Adjuvansni tretman her2-pozitivnog raka dojke
CA3048591A1 (en) * 2017-04-28 2018-11-01 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
SG11202003635TA (en) * 2017-10-26 2020-05-28 Xynomic Pharmaceuticals Inc Crystalline salts of a b-raf kinase inhibitor
BR112020022328A2 (pt) * 2018-05-30 2021-02-02 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. inibidor contendo derivativo tricíclico, método de preparação do mesmo e aplicação do mesmo
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
CA3156625A1 (en) * 2019-11-04 2021-05-14 Houxian ZU Imidazolidinone compound, preparation method therefor and use thereof
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
WO2021104146A1 (zh) * 2019-11-25 2021-06-03 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
KR20240007187A (ko) 2021-05-13 2024-01-16 베타 파머수티컬 컴퍼니 리미티드 이미다졸리디논류 화합물의 다형체, 제조 방법 및 이의 용도
AR125993A1 (es) 2021-05-28 2023-08-30 Genentech Inc Proceso para la preparacion de compuestos de benzoxazepin oxazolidinona

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
ES2102195T3 (es) 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
WO1997019087A1 (en) 1995-11-17 1997-05-29 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
WO2001064675A1 (en) 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
MXPA03006950A (es) 2001-02-02 2003-11-18 Schering Corp Ciclobuteno-1,2-dionas 3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US20040082602A1 (en) 2002-07-19 2004-04-29 Hagen Timothy J. Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
RU2007103816A (ru) * 2004-07-01 2008-08-10 Мерк энд Ко., Инк. (US) Ингибиторы митотического кинезина
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
PL1934174T3 (pl) 2005-10-07 2011-09-30 Exelixis Inc Azetydyny jako inhibitory w leczeniu chorób proliferacyjnych
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
WO2008014483A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
CA2659956C (en) 2006-08-04 2016-01-05 Lewis C. Cantley Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
BRPI0721298A2 (pt) * 2006-12-29 2014-03-25 Abbott Gmbh & Co Kg Composto de carboxamida e seus usos como inibidores de calpaína
US8101740B2 (en) 2007-09-19 2012-01-24 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
CN102333779B (zh) * 2008-03-31 2015-12-09 吉宁特有限公司 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
BR112012006802A2 (pt) * 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
SG10201405049RA (en) * 2009-09-28 2014-10-30 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use

Also Published As

Publication number Publication date
BR112012006807A2 (pt) 2020-11-03
ES2570569T3 (es) 2016-05-19
JP2014070075A (ja) 2014-04-21
CL2012000754A1 (es) 2012-09-07
AU2010299816C1 (en) 2018-02-01
IL217558A (en) 2015-06-30
SI2483278T1 (sl) 2014-03-31
MY184074A (en) 2021-03-17
MY160064A (en) 2017-02-15
MA33531B1 (fr) 2012-08-01
HK1174629A1 (en) 2013-06-14
US8242104B2 (en) 2012-08-14
EP2845592A1 (en) 2015-03-11
JP2013505917A (ja) 2013-02-21
IL239081B (en) 2018-05-31
JP5625101B2 (ja) 2014-11-12
SG10201405049RA (en) 2014-10-30
CN102762576A (zh) 2012-10-31
CO6491026A2 (es) 2012-07-31
RU2654068C1 (ru) 2018-05-16
IL217558A0 (en) 2012-02-29
RU2600927C2 (ru) 2016-10-27
EP2711368B1 (en) 2016-03-23
NZ597833A (en) 2014-01-31
DK2483278T3 (da) 2014-01-13
US8343955B2 (en) 2013-01-01
HRP20140229T1 (hr) 2014-04-11
RS53164B (en) 2014-06-30
ES2444779T3 (es) 2014-02-26
HK1211929A1 (en) 2016-06-03
RU2012117398A (ru) 2013-11-10
CN102762576B (zh) 2015-04-22
CN104744491B (zh) 2017-07-11
US9546178B2 (en) 2017-01-17
US8785626B2 (en) 2014-07-22
AU2010299816B2 (en) 2015-11-12
EP2483278A1 (en) 2012-08-08
ZA201202199B (en) 2013-01-30
IL239081A0 (en) 2015-07-30
EP2711368A1 (en) 2014-03-26
US8586574B2 (en) 2013-11-19
PL2483278T3 (pl) 2014-05-30
US20160052933A1 (en) 2016-02-25
KR20120065431A (ko) 2012-06-20
KR101428346B1 (ko) 2014-08-07
US20120244149A1 (en) 2012-09-27
AR078187A1 (es) 2011-10-19
US9198918B2 (en) 2015-12-01
ECSP12011755A (es) 2012-05-30
JP5540101B2 (ja) 2014-07-02
US20130079331A1 (en) 2013-03-28
CA2772691C (en) 2017-10-03
EP2483278B1 (en) 2013-12-25
WO2011036280A1 (en) 2011-03-31
PE20121025A1 (es) 2012-08-06
PT2483278E (pt) 2014-03-05
CR20120121A (es) 2012-06-01
CA2772691A1 (en) 2011-03-31
TWI423980B (zh) 2014-01-21
US20170081341A1 (en) 2017-03-23
US20140288047A1 (en) 2014-09-25
US9670228B2 (en) 2017-06-06
CN104744491A (zh) 2015-07-01
US20140058098A1 (en) 2014-02-27
US20110076292A1 (en) 2011-03-31
TW201127844A (en) 2011-08-16
AU2010299816A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MX2012003591A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso.
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MY157017A (en) Sulfonamide derivatives
MX2010009739A (es) Inhibidores de cinasa pim y metodos para su uso.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2014MN01433A (es)
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
TN2012000534A1 (en) Pyrazole compounds as sigma receptor inhibitors
TN2013000237A1 (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
MX341446B (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
UA107784C2 (en) Inhibitor of melanin production
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
WO2011041304A3 (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase
WO2010123545A3 (en) Angiogenesis inhibitors
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MX345264B (es) Derivado de azol.
MX345336B (es) Compuestos de benzoxazepina como inhibidores de la pi3k y metodos de uso.
IN2014CN04922A (es)
IN2014MN02433A (es)
WO2008086128A3 (en) Aminopyrazole kinase inhibitors
UA107808C2 (en) Benzoxazepin inhibitors ri3k and their applications

Legal Events

Date Code Title Description
FG Grant or registration